| D007986 |
Luteinizing Hormone |
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. |
ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone |
|
| D009644 |
Norgestrel |
A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis. |
18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-,DL-Norgestrel,Neogest,Ovrette,Postinor,Wy-3707,DL Norgestrel,Wy 3707,Wy3707 |
|
| D011245 |
Pregnadienes |
Pregnane derivatives containing two double bonds anywhere within the ring structures. |
|
|
| D011276 |
Pregnanediol |
An inactive metabolite of PROGESTERONE by reduction at C5, C3, and C20 position. Pregnanediol has two hydroxyl groups, at 3-alpha and 20-alpha. It is detectable in URINE after OVULATION and is found in great quantities in the pregnancy urine. |
|
|
| D011897 |
Random Allocation |
A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. |
Randomization,Allocation, Random |
|
| D002986 |
Clinical Trials as Topic |
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. |
Clinical Trial as Topic |
|
| D003281 |
Contraceptives, Postcoital |
Contraceptive substances to be used after COITUS. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; ANTIMETABOLITES; ALKALOIDS, and PROSTAGLANDINS. |
Emergency Contraceptive,Morning-After Pill,Postcoital Contraceptive,Postcoital Contraceptives,Contraceptive Agents, Post-Coital,Contraceptive Agents, Postcoital,Contraceptives, Post-Coital,Emergency Contraceptives,Contraceptive Agents, Post Coital,Contraceptive, Emergency,Contraceptive, Postcoital,Contraceptives, Emergency,Contraceptives, Post Coital,Morning After Pill,Post-Coital Contraceptive Agents,Post-Coital Contraceptives,Postcoital Contraceptive Agents |
|
| D003283 |
Contraceptives, Postcoital, Synthetic |
Postcoital contraceptives which owe their effectiveness to synthetic preparations. |
Contraceptive Agents, Postcoital, Synthetic,Postcoital Contraceptive Agents, Synthetic,Postcoital Contraceptives, Synthetic,Synthetic Postcoital Contraceptive Agents,Synthetic Postcoital Contraceptives,Contraceptives, Synthetic Postcoital |
|
| D003613 |
Danazol |
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. |
Azol,Cyclomen,Danatrol,Danazant,Danazol-Ratiopharm,Danocrine,Danol,Danoval,Ladogal,Norciden,Panacrine,Danazol Ratiopharm |
|
| D004717 |
Endometrium |
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. |
Endometria |
|